Literature DB >> 16142596

Captopril administered at night restores the diurnal blood pressure rhythm in adequately controlled, nondipping hypertensives.

Yuan-Gang Qiu1, Jian-Hua Zhu, Qian-Min Tao, Ping Zheng, Jun-Zhu Chen, Shen-Jiang Hu, Fu-Rong Zhang, Liang-Rong Zheng, Li-Li Zhao, Xue-Yan Yao.   

Abstract

The aim of our study was to evaluate whether captopril administered at night, can shift the circadian blood pressure (BP) from a nondipper to a dipper pattern in adequately controlled hypertensive patients, who continued their antihypertensive therapy. In a prospective, randomized, double blind, placebo-controlled designed study, we enrolled 121 treated, adequately controlled nondipping hypertensive patients. All patients were randomly assigned to 12.5 mg captopril or placebo treatment administered at night. In case of nondippers, the dosage of captopril or placebo was doubled after two weeks of treatment, while for dippers antihypertensive regimens were not changed. After another two weeks, all patients underwent ambulatory BP monitoring. Our results show that at the end of the active treatment period, the prevalence of a dipping diurnal BP pattern in the captopril group (70%) was significantly higher than that in the placebo group (9.8%, P < 0.001). Nighttime BP, night/day BP ratio, nighttime BP load and 24-h systolic BP were significantly lower after 4 weeks nighttime captopril treatment compared to baseline. In conclusion, the present study demonstrates for the first time that captopril administered at night can restore the diurnal BP rhythm and decrease the elevated night/day BP ratio in appropriately controlled, nondipper hypertensive patients. These results were mainly due to the decrease of nighttime BP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16142596     DOI: 10.1007/s10557-005-1376-0

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  8 in total

Review 1.  Chronotherapeutics of conventional blood pressure-lowering medications: simple, low-cost means of improving management and treatment outcomes of hypertensive-related disorders.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; José R Fernández; Artemio Mojón; Juan J Crespo; María T Ríos; Ana Moyá; Francesco Portaluppi
Journal:  Curr Hypertens Rep       Date:  2014-02       Impact factor: 5.369

Review 2.  Circadian Rhythms, Disease and Chronotherapy.

Authors:  Yool Lee; Jeffrey M Field; Amita Sehgal
Journal:  J Biol Rhythms       Date:  2021-09-22       Impact factor: 3.649

Review 3.  Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; José R Fernández; Artemio Mojón; Francesco Portaluppi
Journal:  Hypertens Res       Date:  2015-12-10       Impact factor: 3.872

4.  Stress, menopausal status and nocturnal blood pressure dipping patterns among hypertensive women.

Authors:  Faye S Routledge; Judith A McFetridge-Durdle; C R Dean
Journal:  Can J Cardiol       Date:  2009-06       Impact factor: 5.223

5.  Nocturnal blood pressure profiles among normotensive, controlled hypertensive and refractory hypertensive subjects.

Authors:  Oded Friedman; Alexander G Logan
Journal:  Can J Cardiol       Date:  2009-09       Impact factor: 5.223

6.  Can nocturnal hypertension predict cardiovascular risk?

Authors:  Oded Friedman; Alexander G Logan
Journal:  Integr Blood Press Control       Date:  2009-09-04

7.  Nocturnal blood pressure elevation predicts progression of albuminuria in elderly people with type 2 diabetes.

Authors:  Walter Palmas; Thomas Pickering; Jeanne Teresi; Joseph E Schwartz; Kazuo Eguchi; Lesley Field; Ruth S Weinstock; Steven Shea
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-01       Impact factor: 3.738

8.  Long-term intake of miso soup decreases nighttime blood pressure in subjects with high-normal blood pressure or stage I hypertension.

Authors:  Hiroaki Kondo; Hiroe Sakuyama Tomari; Shoko Yamakawa; Manabu Kitagawa; Minami Yamada; Seiki Itou; Tetsuro Yamamoto; Yoshio Uehara
Journal:  Hypertens Res       Date:  2019-08-02       Impact factor: 3.872

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.